An accelerated approach
The primary purpose of A-TAP is to provide the missing link that will ensure that world-class basic science observations are ‘accelerated’ into early-phase experimental therapy for patients by providing the ‘infrastructure of people’ to allow this to happen.
Simply put, A-TAP is bringing together the right people to develop the right drug for the right disease as quickly and efficiently as possible using clinical trials.
The A-TAP team are bringing an innovative new approach to translational inflammation research. The team are accelerating the assessment of novel therapies in the clinic by using pathology-based outcome measures in basket trials; testing the effect of one drug on a single mutation in a variety of disease types, at the same time.
Professor Chris Buckley, Kennedy Professor of Translational Rheumatology at the Kennedy Institute, a dual role held between both universities, explains:
“There is something that I call the ‘Goldilocks paradox’ – how big is big and how small is small. For each disease there is a good size; if you’re too big you don’t have the patients but if you’re too small you don’t have the power. Through A-TAP we are able to reach 5 million patients, which is about right for what we are trying to achieve.”
The outcomes will help treat the cause of disease, not just the symptoms, and ensure treatments are targeted to patients who are most likely to benefit. The A-TAP team are targeting RA, Sjögren’s syndrome, inflammatory bowel disease, and spondyloarthropathy first.